No Cover Image

Journal article 360 views 278 downloads

Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies

Nicolò Matteo Luca Battisti Orcid Logo, Catherine A. Welch, Michael Sweeting, Mark de Belder, John Deanfield, Clive Weston Orcid Logo, Michael D. Peake, David Adlam, Alistair Ring

JACC: CardioOncology, Volume: 4, Issue: 2, Pages: 238 - 253

Swansea University Author: Clive Weston Orcid Logo

  • 60319.VOR.pdf

    PDF | Version of Record

    Distributed under the terms of a Creative Commons Attribution 4.0 CC BY Licence.

    Download (1.83MB)

Check full text

DOI (Published version): 10.1016/j.jaccao.2022.03.004

Abstract

BackgroundAlthough a common challenge for patients and clinicians, there is little population-level evidence on the prevalence of cardiovascular disease (CVD) in individuals diagnosed with potentially curable cancer.ObjectivesWe investigated CVD rates in patients with common potentially curable mali...

Full description

Published in: JACC: CardioOncology
ISSN: 2666-0873
Published: Elsevier BV 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60319
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-06-24T12:06:37Z
last_indexed 2023-01-13T19:20:21Z
id cronfa60319
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-07-15T11:16:50.2371133</datestamp><bib-version>v2</bib-version><id>60319</id><entry>2022-06-24</entry><title>Prevalence of Cardiovascular Disease&#xA0;in&#xA0;Patients With Potentially Curable&#xA0;Malignancies</title><swanseaauthors><author><sid>df85e4e0e139d0f46eb683174eba98a9</sid><ORCID>0000-0002-8995-8199</ORCID><firstname>Clive</firstname><surname>Weston</surname><name>Clive Weston</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-06-24</date><deptcode>PMSC</deptcode><abstract>BackgroundAlthough a common challenge for patients and clinicians, there is little population-level evidence on the prevalence of cardiovascular disease (CVD) in individuals diagnosed with potentially curable cancer.ObjectivesWe investigated CVD rates in patients with common potentially curable malignancies and evaluated the associations between patient and disease characteristics and CVD prevalence.MethodsThe study included cancer registry patients diagnosed in England with stage I to III breast cancer, stage I to III colon or rectal cancer, stage I to III prostate cancer, stage I to IIIA non-small-cell lung cancer, stage I to IV diffuse large B-cell lymphoma, and stage I to IV Hodgkin lymphoma from 2013 to 2018. Linked hospital records and national CVD databases were used to identify CVD. The rates of CVD were investigated according to tumor type, and associations between patient and disease characteristics and CVD prevalence were determined.ResultsAmong the 634,240 patients included, 102,834 (16.2%) had prior CVD. Men, older patients, and those living in deprived areas had higher CVD rates. Prevalence was highest for non-small-cell lung cancer (36.1%) and lowest for breast cancer (7.7%). After adjustment for age, sex, the income domain of the Index of Multiple Deprivation, and Charlson comorbidity index, CVD remained higher in other tumor types compared to breast cancer patients.ConclusionsThere is a significant overlap between cancer and CVD burden. It is essential to consider CVD when evaluating national and international treatment patterns and cancer outcomes.</abstract><type>Journal Article</type><journal>JACC: CardioOncology</journal><volume>4</volume><journalNumber>2</journalNumber><paginationStart>238</paginationStart><paginationEnd>253</paginationEnd><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2666-0873</issnPrint><issnElectronic/><keywords>breast cancer; colorectal cancer; lung cancer; lymphoma; prostate cancer</keywords><publishedDay>21</publishedDay><publishedMonth>6</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-06-21</publishedDate><doi>10.1016/j.jaccao.2022.03.004</doi><url/><notes/><college>COLLEGE NANME</college><department>Medicine</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>PMSC</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>This study was funded by a joint research grant from the British Heart Foundation (SP/16/5/32415) and Cancer Research UK (C53325/A21134).</funders><lastEdited>2022-07-15T11:16:50.2371133</lastEdited><Created>2022-06-24T13:01:13.4563625</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Nicol&#xF2; Matteo Luca</firstname><surname>Battisti</surname><orcid>0000-0002-1063-1717</orcid><order>1</order></author><author><firstname>Catherine A.</firstname><surname>Welch</surname><order>2</order></author><author><firstname>Michael</firstname><surname>Sweeting</surname><order>3</order></author><author><firstname>Mark de</firstname><surname>Belder</surname><order>4</order></author><author><firstname>John</firstname><surname>Deanfield</surname><order>5</order></author><author><firstname>Clive</firstname><surname>Weston</surname><orcid>0000-0002-8995-8199</orcid><order>6</order></author><author><firstname>Michael D.</firstname><surname>Peake</surname><order>7</order></author><author><firstname>David</firstname><surname>Adlam</surname><order>8</order></author><author><firstname>Alistair</firstname><surname>Ring</surname><order>9</order></author></authors><documents><document><filename>60319__24394__ae463ad82c3d4205bb46e1b3cc970a83.pdf</filename><originalFilename>60319.VOR.pdf</originalFilename><uploaded>2022-06-24T13:06:57.2918979</uploaded><type>Output</type><contentLength>1921002</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Distributed under the terms of a Creative Commons Attribution 4.0 CC BY Licence.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-07-15T11:16:50.2371133 v2 60319 2022-06-24 Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies df85e4e0e139d0f46eb683174eba98a9 0000-0002-8995-8199 Clive Weston Clive Weston true false 2022-06-24 PMSC BackgroundAlthough a common challenge for patients and clinicians, there is little population-level evidence on the prevalence of cardiovascular disease (CVD) in individuals diagnosed with potentially curable cancer.ObjectivesWe investigated CVD rates in patients with common potentially curable malignancies and evaluated the associations between patient and disease characteristics and CVD prevalence.MethodsThe study included cancer registry patients diagnosed in England with stage I to III breast cancer, stage I to III colon or rectal cancer, stage I to III prostate cancer, stage I to IIIA non-small-cell lung cancer, stage I to IV diffuse large B-cell lymphoma, and stage I to IV Hodgkin lymphoma from 2013 to 2018. Linked hospital records and national CVD databases were used to identify CVD. The rates of CVD were investigated according to tumor type, and associations between patient and disease characteristics and CVD prevalence were determined.ResultsAmong the 634,240 patients included, 102,834 (16.2%) had prior CVD. Men, older patients, and those living in deprived areas had higher CVD rates. Prevalence was highest for non-small-cell lung cancer (36.1%) and lowest for breast cancer (7.7%). After adjustment for age, sex, the income domain of the Index of Multiple Deprivation, and Charlson comorbidity index, CVD remained higher in other tumor types compared to breast cancer patients.ConclusionsThere is a significant overlap between cancer and CVD burden. It is essential to consider CVD when evaluating national and international treatment patterns and cancer outcomes. Journal Article JACC: CardioOncology 4 2 238 253 Elsevier BV 2666-0873 breast cancer; colorectal cancer; lung cancer; lymphoma; prostate cancer 21 6 2022 2022-06-21 10.1016/j.jaccao.2022.03.004 COLLEGE NANME Medicine COLLEGE CODE PMSC Swansea University Another institution paid the OA fee This study was funded by a joint research grant from the British Heart Foundation (SP/16/5/32415) and Cancer Research UK (C53325/A21134). 2022-07-15T11:16:50.2371133 2022-06-24T13:01:13.4563625 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Nicolò Matteo Luca Battisti 0000-0002-1063-1717 1 Catherine A. Welch 2 Michael Sweeting 3 Mark de Belder 4 John Deanfield 5 Clive Weston 0000-0002-8995-8199 6 Michael D. Peake 7 David Adlam 8 Alistair Ring 9 60319__24394__ae463ad82c3d4205bb46e1b3cc970a83.pdf 60319.VOR.pdf 2022-06-24T13:06:57.2918979 Output 1921002 application/pdf Version of Record true Distributed under the terms of a Creative Commons Attribution 4.0 CC BY Licence. true eng https://creativecommons.org/licenses/by/4.0/
title Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies
spellingShingle Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies
Clive Weston
title_short Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies
title_full Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies
title_fullStr Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies
title_full_unstemmed Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies
title_sort Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies
author_id_str_mv df85e4e0e139d0f46eb683174eba98a9
author_id_fullname_str_mv df85e4e0e139d0f46eb683174eba98a9_***_Clive Weston
author Clive Weston
author2 Nicolò Matteo Luca Battisti
Catherine A. Welch
Michael Sweeting
Mark de Belder
John Deanfield
Clive Weston
Michael D. Peake
David Adlam
Alistair Ring
format Journal article
container_title JACC: CardioOncology
container_volume 4
container_issue 2
container_start_page 238
publishDate 2022
institution Swansea University
issn 2666-0873
doi_str_mv 10.1016/j.jaccao.2022.03.004
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description BackgroundAlthough a common challenge for patients and clinicians, there is little population-level evidence on the prevalence of cardiovascular disease (CVD) in individuals diagnosed with potentially curable cancer.ObjectivesWe investigated CVD rates in patients with common potentially curable malignancies and evaluated the associations between patient and disease characteristics and CVD prevalence.MethodsThe study included cancer registry patients diagnosed in England with stage I to III breast cancer, stage I to III colon or rectal cancer, stage I to III prostate cancer, stage I to IIIA non-small-cell lung cancer, stage I to IV diffuse large B-cell lymphoma, and stage I to IV Hodgkin lymphoma from 2013 to 2018. Linked hospital records and national CVD databases were used to identify CVD. The rates of CVD were investigated according to tumor type, and associations between patient and disease characteristics and CVD prevalence were determined.ResultsAmong the 634,240 patients included, 102,834 (16.2%) had prior CVD. Men, older patients, and those living in deprived areas had higher CVD rates. Prevalence was highest for non-small-cell lung cancer (36.1%) and lowest for breast cancer (7.7%). After adjustment for age, sex, the income domain of the Index of Multiple Deprivation, and Charlson comorbidity index, CVD remained higher in other tumor types compared to breast cancer patients.ConclusionsThere is a significant overlap between cancer and CVD burden. It is essential to consider CVD when evaluating national and international treatment patterns and cancer outcomes.
published_date 2022-06-21T04:18:20Z
_version_ 1763754220419284992
score 11.035634

Similar Items